Search Results
74 Results Found for “microglia”
Could NLRP3 be the missing link between amyloid pathology and tau-mediated neurodegeneration? Dr Gennaro Pagano explains how insights from the GRADUATE trial is informing the next generation of Alzheimer's disease therapies and advancing our understanding of neuroinflammation. https://touchmedicalmedia-1.wistia.
We are delighted to announce Dr Brandon Holmes as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of neurodegenerative disease. We spoke with Dr Brandon Holmes (Memory and Aging Center and Weill Institute ...
Dr Micah Luftig discusses the implications for clinical risk stratification and early intervention, and how EBV-targeted strategies may shape future therapeutic approaches Growing evidence has positioned Epstein–Barr virus (EBV) as a central factor in the development of multiple sclerosis (...
The Bidirectional Nexus of Sleep and Alzheimer’s Disease: Mechanisms and Translational Opportunities
Alzheimer’s disease (AD), the most prevalent cause of dementia, is a progressive neurodegenerative disorder marked by the abnormal accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles. It currently affects more than 50 million individuals worldwide, with projections reaching over 210 ...
Between 60% and 80% of cases with dementia worldwide are caused by Alzheimer’s disease (AD), making it the most prevalent type of dementia.1 As of 2025, approximately 60 million people worldwide are affected by dementia, and by 2050, projections suggest a rise to nearly 210 ...
Huntington’s disease (HD) is a fatal, autosomal-dominant, neurodegenerative disorder caused by a cytosine–adenine–guanine (CAG) trinucleotide repeat expansion in the huntingtin (HTT) gene, located on chromosome 4p16.3. When this repeat exceeds 36 units, it leads to the synthesis of ...
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress, held in Barcelona, brought together over 9,600 global experts under the theme “A New Era of Precision.” This report, developed in collaboration with the National Multiple Sclerosis Society, highlights key breakthroughs in diagnosis, treatment, and lifestyle interventions—including advances in ocrelizumab, BTK inhibitors, myelin repair strategies, and early biomarkers. With new insights into cognition, menopause, and precision medicine, ECTRIMS 2025 underscored the shift toward truly personalised, data-driven MS care.
Recent advances in the understanding of agitation in Alzheimer's have informed the development of targeted therapies. In this expert interview, Dr George Grossberg (Saint Louis University School of Medicine, St Louis, MO, USA), an authority in geriatric psychiatry, shares his perspective on the pathophysiological underpinnings of agitation in Alzheimer’s disease, current and emerging pharmacological approaches, and the implications of findings presented at the Alzheimer’s Association International Conference (AAIC) 2025.
In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.
A new study published in Nature Neuroscience1 has uncovered significant insights into the progression of Alzheimer’s disease (AD), providing a new understanding of how the disease damages the brain. Funded by the National Institutes of Health (NIH) and led by researchers from the Allen Institute, this study used advanced brain mapping and genetic tools to explore the cellular-level changes that occur throughout AD. The findings reveal that Alzheimer's progresses in two distinct phases, offering potential avenues for early diagnosis and treatment strategies.
Affecting over 70 million patients worldwide, epilepsy is a chronic neurological disorder characterized by intermittent bursts of hyper-synchronous neuronal discharges.1 The manifestations are variable but reflective of the unique milieu and biology of epileptogenic foci.2 Pharmacological treatment with antiepileptic drugs (AEDs) ...
Introduction The term 'stroke' is used to describe an adverse clinical state involving interference of blood circulation to the brain due to obstruction or rupture of blood vessels.1 Stroke was previously categorized into a cardiovascular disorder until the release of ...
The discovery of the rapid antidepressant effects of ketamine shifted the biology and treatment of psychiatric disorders, emphasizing targeting glutamate signaling, rather than monoamine signaling, for schizophrenia and depression. Research highlights synaptic deficits, network disinhibition, and synaptic loss in schizophrenia, ...
The coronavirus disease 2019 (COVID-19) pandemic has led to unprecedented illness and death among the global population. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can range from mild upper respiratory symptoms that subside with no lasting effects to multiorgan system failure ...
The effect of TREM2 on neurodegenerative diagnosis, cognitive profile and brain structure are discussed in this touchNEUROLOGY interview with Dr Oliver Cousins (King's College London, London, UK). Microglial genes are risk factors for neurodegenerative disease. This study investigated the association ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
